
Navigating the “Plausibility” Maze: When Can You Rely on Post-Filed Evidence in Pharma & Biotech?
For innovative pharmaceutical companies, that question can determine the fate of a blockbuster. In T 0592/24, the EPO Boards of Appeal provided one of their
